Lower-dose chemo for older women with HER2-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older.
- You have been diagnosed with stage I, II, or III breast cancer that is HER2-negative.
- Your doctor has recommended chemotherapy with docetaxel and cyclophosphamide, either before or after surgery.
- You have not already received chemotherapy for this breast cancer.
- You are willing to fill out questionnaires about your health and well-being.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
This trial is testing a lower dose of treatment for women with small, early-stage breast cancer that is hormone-positive and has not spread to lymph nodes. The goal is to find out if it can be as effective as the standard treatment with fewer side effects.
This trial tests a combination of two targeted drugs (trastuzumab and pertuzumab) and a low-dose chemotherapy (vinorelbine) given before surgery to shrink HER2-positive breast tumors in older adults. The goal is to reduce the tumor size to make surgery easier and hopefully improve outcomes.
This trial tests a new drug that targets breast cancer cells with low levels of the HER2 protein. It may offer a new treatment option for patients whose cancer has spread and not responded well to previous therapies.
This trial tests whether women aged 65 and older with a certain type of early breast cancer can safely skip chemotherapy and instead receive a pill that helps stop cancer cells from growing. The goal is to reduce treatment side effects while keeping the cancer from coming back.
Hear when a new Anatomic Stage I Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.